机构:[1]Department of Pathology, The Fourth Hospital of Hebei Medical University & Hebei Tumor Hospital, Hebei Province, Shijiazhuang, China医技科室病理科河北医科大学第四医院
第一作者机构:[1]Department of Pathology, The Fourth Hospital of Hebei Medical University & Hebei Tumor Hospital, Hebei Province, Shijiazhuang, China
通讯作者:
通讯机构:[1]Department of Pathology, The Fourth Hospital of Hebei Medical University & Hebei Tumor Hospital, Hebei Province, Shijiazhuang, China
推荐引用方式(GB/T 7714):
Liu Yao,Liu Yu,Jiao W P.MiR-139 Affects Radioresistance in Esophageal Cancer by Targeting the PDK1/AKT/Cyclin D1 Signaling Pathway[J].BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE.2023,174(4):489-496.doi:10.1007/s10517-023-05735-z.
APA:
Liu Yao,Liu Yu&Jiao W P.(2023).MiR-139 Affects Radioresistance in Esophageal Cancer by Targeting the PDK1/AKT/Cyclin D1 Signaling Pathway.BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE,174,(4)
MLA:
Liu Yao,et al."MiR-139 Affects Radioresistance in Esophageal Cancer by Targeting the PDK1/AKT/Cyclin D1 Signaling Pathway".BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE 174..4(2023):489-496